Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
2.890
+0.020 (0.70%)
At close: Aug 14, 2026, 4:00 PM EDT
2.940
+0.050 (1.73%)
After-hours: Aug 14, 2026, 7:34 PM EDT
Entera Bio Employees
As of March 31, 2026, Entera Bio had 22 total employees, including 20 full-time and 2 part-time employees. The number of employees increased by 2 or 10.00% compared to the same quarter last year.
Employees
22
Change
2
Growth
10.00%
Revenue / Employee
n/a
Profits / Employee
-$774,227
Market Cap
500.38M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2026 | 22 | 2 | 10.00% | 20 | 2 |
| Dec 31, 2025 | 22 | 2 | 10.00% | 20 | 2 |
| Sep 30, 2025 | 22 | 2 | 10.00% | 20 | 2 |
| Jun 30, 2025 | 21 | 2 | 10.53% | 19 | 2 |
| Mar 31, 2025 | 20 | 1 | 5.26% | 18 | 2 |
| Dec 31, 2024 | 20 | 2 | 11.11% | 18 | 2 |
| Sep 30, 2024 | 20 | -1 | -4.76% | 18 | 2 |
| Jun 30, 2024 | 19 | -2 | -9.52% | 17 | 2 |
| Mar 31, 2024 | 19 | 1 | 5.56% | 17 | 2 |
| Dec 31, 2023 | 18 | 1 | 5.88% | 17 | 1 |
| Sep 30, 2023 | 21 | 2 | 10.53% | 19 | 2 |
| Jun 30, 2023 | 21 | -1 | -4.55% | 19 | 2 |
| Mar 31, 2023 | 18 | -3 | -14.29% | 18 | 0 |
| Dec 31, 2022 | 17 | -3 | -15.00% | 15 | 2 |
| Sep 30, 2022 | 19 | -4 | -17.39% | 19 | 0 |
| Jun 30, 2022 | 22 | 3 | 15.79% | 22 | 0 |
| Mar 31, 2022 | 21 | 2 | 10.53% | 21 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 485 |
| MapLight Therapeutics | 133 |
| Kyverna Therapeutics | 129 |
| Adlai Nortye | 109 |
| C4 Therapeutics | 104 |
| OmniAb | 89 |
| Rezolute | 68 |
| Ovid Therapeutics | 23 |
ENTX News
- 2 days ago - Entera Bio Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 7 days ago - Entera Announces Second Quarter 2026 Financial Results and Business Updates - GlobeNewsWire
- 7 days ago - Entera Bio Quarterly report: Q2 2026 - Filings
- 7 days ago - Entera Bio Earnings release: Q2 2026 - Filings
- 10 days ago - Entera Bio Phase 2 Data Supporting EB613's (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting - GlobeNewsWire
- 14 days ago - Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference - GlobeNewsWire
- 16 days ago - Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE - PRNewsWire
- 18 days ago - Entera Bio announces $275M private placement - TheFly